Advice
Following a full submission
Ibandronic acid (Bonviva) is accepted for use within NHS Scotland for the treatment of osteoporosis in postmenopausal women in order to reduce the risk of vertebral fractures.
Ibandronic acid 150mg monthly is superior to daily ibandronic acid in terms of lumbar spine bone mineral density at 1 year. Compared with placebo, daily administration of ibandronic acid results in a relative risk reduction for vertebral fractures of 62%. Unlike some other bisphosphonates, efficacy in reducing femoral neck fractures (and other non-vertebral fractures) has not been established.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- Ibandronic acid (Bonviva®)
- SMC ID:
- 228/05
- Indication:
- Osteoporosis in postmenopausal women in order to reduce the risk of vertebral fractures
- Pharmaceutical company
- Roche
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 February 2006